KeyBanc upgraded Acadia Healthcare (ACHC) to Overweight from Sector Weight with a $70 price target The stock “could inflect meaningfully higher” during 2025, as investors gain visibility into the potential 2026 EBITDA acceleration, the analyst tells investors in a research note. The firm says the company’s 2026 EBITDA will benefit from the maturation of 2024-2025 bed adds and moderating startup costs. KeyBanc believes Acadia ‘s valuation “can begin to normalize” during 2025 as negative press headlines from 2024 fade and 2026 EBITDA comes into focus.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare upgraded to Buy from Hold at Deutsche Bank
- Cantor Fitzgerald ‘cautious’ on Acadia after survey of inpatient psych referrers
- Acadia down 1% following NY Times expose on ‘fraud and fakery’ at clinics
- Acadia Healthcare falsifies records at methadone clinics, NY Times says
- Acadia Healthcare price target lowered to $43 from $76 at Barclays